Delivery Order SPE2DB22D1106-SPE2DB25FEYY1
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Multaq 400 mg tablets in a quantity of 60 units, valued at $24,080.88 under a firm fixed-price contract. This is a non-set-aside award, meaning it was competitively procured and open to all qualified vendors. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,170.01 to AmerisourceBergen Drug Corp for the supply of Multaq 400 mg tablets (60-count units) on July 21, 2025, with completion scheduled for July 22, 2025. This competitively awarded, firm fixed-price delivery order was issued without set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen Drug...
- This delivery order, awarded on July 21, 2025, by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, is for the supply of Multaq 400 mg tablets (60-count units) with a ceiling value of $7,781.08. The contract utilizes a firm fixed price structure and is non-competitive, with an ultimate completion date of July 22, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfills this order from its corporate office...
- The U.S. Department of Defense Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $20,853.40 for 60 tablets of Multaq 400 mg on July 21, 2025, with an ultimate completion date of July 22, 2025. This non-set-aside contract utilizes firm fixed price terms and represents a single delivery order under a larger indefinite delivery contract vehicle. The point of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen's corporate office operates as...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to supply Multaq 400 mg tablets. The $26,758.04 delivery order was placed under an existing $999,999,999.00 indefinite delivery contract (IDC) held by AmerisourceBergen Drug Corp to provide a comprehensive range of pharmaceutical products and medical supplies to DLA Troop Support Medical facilities supporting the Department of Defense. This...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $35,078.41 to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Multaq 400 mg tablets (60-count packages). This firm fixed-price delivery order, with an ultimate completion date of July 22, 2025, represents a competitive award with no set-aside designation and is performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Multaq 400 mg tablets. The award is for a Firm Fixed Price contract with a ceiling value of $14,819.35 and a completion date of September 7, 2023. This order is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen Drug Corp holds with DLA Troop Support Medical, valued at up to $999,999,999.00 through December 2026....
- The Defense Logistics Agency Troop Support Medical awarded a firm fixed price delivery order valued at approximately $47,000 to Amerisourcebergen Drug Corp for the supply of 60 units of 400mg Multaq tablets. As the prime contractor, Amerisourcebergen Drug Corp will deliver the pharmaceutical products to a location in Conshohocken, Pennsylvania under a one day period of performance from July 10-11, 2023. The award was issued against an existing indefinite-delivery/indefinite-quantity contract...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The $21,298.99 firm-fixed-price delivery order is for the supply of Multaq 400 mg tablets. The contract has a period of performance through May 9, 2025 and is not set aside. Amerisourcebergen holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, with a ceiling value of $16,945.56, is for the delivery of Multaq 400 mg tablets over a period ending on May 23, 2024. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical. This IDC serves as...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FEYY1Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $26,287.49 to AmerisourceBergen Drug Corp for the supply of Multaq 400 mg tablets (60-count packages). This competitively awarded, firm fixed-price contract was issued on July 21, 2025, with an ultimate completion date of July 22, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery from its corporate office location. This delivery order represents a child contract under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (contract SPE2DX), valued at $999,999,999 and extending through December 2026. The Multaq pharmaceutical supply falls within AmerisourceBergen Drug Corp's comprehensive portfolio of medications and medical supplies provided to support military healthcare systems and federal medical procurement needs. As a critical vendor for the Defense Logistics Agency's Medical Supply Chain, the company supplies an extensive range of pharmaceutical products spanning multiple therapeutic domains to support defense health programs worldwide. The non-set-aside status of this award reflects AmerisourceBergen Drug Corp's demonstrated capability to compete successfully in open federal pharmaceutical procurement, consistent with its track record of fulfilling federal medical supply requirements across varied product categories and transaction values.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $26.3k | 7/21/25 |